Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
S Ostrowitzki, D Deptula, L Thurfjell… - Archives of …, 2012 - jamanetwork.com
Background Gantenerumab is a fully human anti-Aβ monoclonal antibody in clinical
development for the treatment of Alzheimer disease (AD). Objectives To investigate whether …
development for the treatment of Alzheimer disease (AD). Objectives To investigate whether …
[HTML][HTML] A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease
S Ostrowitzki, RA Lasser, E Dorflinger… - Alzheimer's research & …, 2017 - Springer
Background Gantenerumab is a fully human monoclonal antibody that binds aggregated
amyloid-β (Aβ) and removes Aβ plaques by Fc receptor-mediated phagocytosis. In the SCarlet …
amyloid-β (Aβ) and removes Aβ plaques by Fc receptor-mediated phagocytosis. In the SCarlet …
First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers
…, W Zago, J Soto, G Atiee, S Ostrowitzki… - Movement …, 2017 - Wiley Online Library
Background: α‐Synuclein is a major component of pathologic inclusions that characterize
Parkinson's disease. PRX002 is an antibody that targets α‐synuclein, and its murine parent …
Parkinson's disease. PRX002 is an antibody that targets α‐synuclein, and its murine parent …
Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti–α-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized …
…, SG Griffith, M Grundman, J Soto, S Ostrowitzki… - JAMA …, 2018 - jamanetwork.com
Importance Aggregated α-synuclein is believed to be central to the pathogenesis of Parkinson
disease (PD). PRX002/RG7935 (PRX002) is a humanized monoclonal antibody designed …
disease (PD). PRX002/RG7935 (PRX002) is a humanized monoclonal antibody designed …
Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials
S Ostrowitzki, T Bittner, KM Sink, H Mackey… - JAMA …, 2022 - jamanetwork.com
Importance Alzheimer disease (AD), a neurodegenerative disease characterized by β-amyloid
plaques and τ tangles in the brain, represents an unmet medical need with no fully …
plaques and τ tangles in the brain, represents an unmet medical need with no fully …
Assessing tumor angiogenesis using macromolecular MR imaging contrast media
…, N Van Bruggen, J Mann, S Ostrowitzki… - Journal of magnetic …, 1997 - Wiley Online Library
MRI enhanced with a macromolecular contrast medium (MMCM) has previously been
shown to estimate tumor microvascular characteristics that correlate closely with histologic …
shown to estimate tumor microvascular characteristics that correlate closely with histologic …
Tau: From research to clinical development
…, EM Mandelkow, DS Miller, S Ostrowitzki… - Alzheimer's & …, 2016 - Elsevier
Alzheimer's Association Research Roundtable Fall 2015—Tau: From research to clinical
development. Tau pathology is recognized as the key driver of disease progression in …
development. Tau pathology is recognized as the key driver of disease progression in …
[HTML][HTML] A phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson's disease (PASADENA): rationale, design, and baseline data
…, H Svoboda, M Britschgi, S Ostrowitzki… - Frontiers in …, 2021 - frontiersin.org
Background: Currently available treatments for Parkinson's disease (PD) do not slow clinical
progression nor target alpha-synuclein, a key protein associated with the disease. Objective…
progression nor target alpha-synuclein, a key protein associated with the disease. Objective…
Characterization of 3 novel tau radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in healthy controls and in Alzheimer subjects
…, SM Resnick, S Ostrowitzki… - Journal of Nuclear …, 2018 - Soc Nuclear Med
11 C-RO-963, 11 C-RO-643, and 18 F-RO-948 (previously referred to as 11 C-RO6924963,
11 C-RO6931643, and 18 F-RO6958948, respectively) have been reported as promising …
11 C-RO6931643, and 18 F-RO6958948, respectively) have been reported as promising …
[HTML][HTML] Safety, tolerability, and pharmacokinetics of crenezumab in patients with mild-to-moderate Alzheimer's disease treated with escalating doses for up to 133 …
…, D Clayton, J Smith, S Ostrowitzki - Journal of …, 2020 - content.iospress.com
Background: Crenezumab is a fully humanized, monoclonal anti-amyloid-β immunoglobulin
G4 antibody. Objective: This Phase Ib study (NCT02353598) evaluated the safety, tolerability…
G4 antibody. Objective: This Phase Ib study (NCT02353598) evaluated the safety, tolerability…